In fact, a phase 1 clinical study is currently investigating the combination of an ALK‐TKI, ceritinib, with a MEK inhibitor, trametinib, in ALK+ or ROS1+ NSCLC patients [69]. This evidence concerns the gene ALK and non-small cell lung carcinoma.